11 completed. 11 Phase 2, 3 Phase 3, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 11 | Completed 11 |
| Phase 3 | 3 | Completed 3 |
| Phase 1 | 2 | Completed 2 |
Follow SARS CoV 2 Infection: new trials by email Literature Review of SARS CoV 2 Infection trials Research Report on SARS CoV 2 Infection
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2 IMNN-101 - SARS CoV 2 Infection | Phase 1 / Phase 2 | Completed | Imunon | 24 | 2024-06-04 | 2025-07-23 |
| A Phase II Trial to Evaluate the Safety and Immunogenicity of BIMERVAX® When Coadministered With Seasonal Influenza Vaccine (SIIV) in Adults Older Than 65 Years of Age Fully Vaccinated Against COVID-19 BIMERVAX, SIIV - SARS CoV 2 Infection, Influenza, Human | Phase 2 | Completed | Hipra Scientific, S.L.U | 279 | 2023-09-04 | 2024-02-26 |
| Open-label, Multi-centre, Non-Inferiority Study of Safety and Immunogenicity of BIMERVAX for the Prevention of COVID-19 in Adolescents From 12 Years to Less Than 18 Years of Age. BIMERVAX - SARS CoV 2 Infection | Phase 2 | Completed | Hipra Scientific, S.L.U | 242 | 2023-06-08 | 2026-03-12 |
| Safety and Immunogenicity of Omicron Variant-Matched Vaccine Booster in Adults mRNA-1273.214 Vaccine, MRNA-1273 Vaccine, Placebo - COVID-19 Pandemic, Immunogenicity | Phase 2 | Completed | Sheba Medical Center | 179 | 2022-09-05 | 2024-02-21 |
| Evaluating Safety and Immune Response of Janssen, Moderna, Pfizer/BNT, and Novavax COVID-19 Vaccines for Same and Mixed Boosters in Adolescents and Adults Aged 12-64 With and Without HIV in Kenya, DRC, and Rwanda Janssen Ad26COVS1, Pfizer-BioNTech vaccine COVID-19 vaccine, Inactivated Sinopharm or Sinovac COVID-19 vaccine - COVID -19, SARS CoV 2 Infection | Phase 2 | Completed | Victoria Biomedical Research Institute | 1919 | 2022-05-18 | 2026-02-13 |
| Inhibition of Bradykinin in COVID-19 Infection With Icatibant Icatibant, 0.9% Sodium Chloride Injection - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Belfast Health and Social Care Trust | 32 | 2022-05-16 | 2023-09-07 |
| A Phase IIb/III Clinical Trial to Assess Safety and Immunogenicity of a COVID-19 Vaccine Booster Dose in Immunosupressed Adults. PHH-1V - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Hipra Scientific, S.L.U | 241 | 2022-05-12 | 2025-09-16 |
| A Safety and Tolerability Study of Sotrovimab (VIR-7831) Prophylaxis Against COVID-19 in Immunocompromised Individuals Sotrovimab - SARS CoV 2 Infection | Phase 2 | Completed | Sophia Koo, M.D. | 93 | 2022-02-07 | 2024-08-15 |
| Phase II Study of AVX/COVID-12 Vaccine in Subjects With Prior SARS-CoV-2 Immunity Evidence Recombinant NDV Vectored Vaccine for SARS-CoV-2, Placebo - SARS CoV 2 Infection | Phase 2 | Completed | Laboratorio Avi-Mex, S.A. de C.V. | 158 | 2021-11-23 | 2025-10-02 |
| Safety and Immunogenicity Study of Recombinant Protein RBD Candidate Vaccine Against SARS-CoV-2 in Adult Healthy Volunteers (COVID-19) COVID-19 vaccine HIPRA 10, COVID-19 vaccine HIPRA 20, COVID-19 vaccine HIPRA 40 - Covid19, SARS CoV 2 Infection | Phase 1 / Phase 2 | Completed | Laboratorios Hipra, S.A. | 30 | 2021-08-16 | 2023-03-01 |
| Multicenter Double Blind, Parallel-group Phase 2/3 Trial, to Study Raloxifene in Adult COVID-19 Patients. Raloxifene, Placebo - SARS CoV 2 Infection | Phase 2 / Phase 3 | Completed | Dompé Farmaceutici S.p.A | 61 | 2021-01-22 | 2023-12-26 |
COVID-19 (11) · Influenza, Human (1) · Pneumonia (1)
Coronaviridae Infections (11) · Coronavirus Infections (11) · Infections (11) · Lung Diseases (11) · Nidovirales Infections (11) · Pneumonia, Viral (11) · RNA Virus Infections (11) · Respiratory Tract Diseases (11) · Respiratory Tract Infections (11) · Virus Diseases (11) · Pneumonia (10) · Orthomyxoviridae Infections (1)
2019-nCoV Vaccine mRNA-1273 (1) · BNT162 Vaccine (1) · HIPRA COVID-19 vaccine (1) · KPNA1 protein, human (1) · Raloxifene Hydrochloride (1) · Sodium Chloride (1) · icatibant (1) · mRNA-1273.214 COVID-19 vaccine (1) · sinovac COVID-19 vaccine (1) · sotrovimab (1)
Hipra Scientific, S.L.U (3) · Belfast Health and Social Care Trust (1) · Dompé Farmaceutici S.p.A (1) · Imunon (1) · Laboratorio Avi-Mex, S.A. de C.V. (1) · Laboratorios Hipra, S.A. (1) · Sheba Medical Center (1) · Sophia Koo, M.D. (1) · Victoria Biomedical Research Institute (1)
Spain (5) · United States (2) · France (1) · Israel (1) · Italy (1) · Kenya (1) · Mexico (1) · Turkey (Türkiye) (1) · United Kingdom (1)
Douglas Faller, MD (1) · Elia Torroella (1) · Francesco Sergio, MD, PhD (1) · Gili Regev-Yochay, MD (1) · Jennifer Manne-Goehler, MD, ScD (1) · Joe Kidney, MD (1) · Laura Castro, MD (1) · Niels Hansen, MD (1) · Sarah P Hammond, MD (1) · Sophia Koo, MD (1)
PMID 35582123, PMID 36435633, PMID 37328890, PMID 37775521, PMID 38035747, PMID 38806352, PMID 39527880